Table 1.
Study population characteristics.*
| Patients - no. | 738 |
| Age - years, mean (SD) | 58 (17) |
| Sex - no. (%) female | 392 (53) |
| Disease - no. (%) | |
| AAV | 529 (72) |
| LN | 24 (3) |
| MN | 73 (10) |
| MCD/FSGS | 59 (8) |
| Other | 53 (7) |
| Rituximab - no. of doses | 8 (5, 12) |
| Duration of B cell depletion - years | 2.5 (1.4, 4.5) |
| AAV | 2.8 (1.4, 5.1) |
| LN | 2.4 (1.8, 4.6) |
| MN | 2.2 (1.4, 2.6) |
| MCD/FSGS | 2.4 (1.5, 3.2) |
| Other | 1.4 (0.7, 3.6) |
| CYC use - no. (%) | |
| Never | 170 (23) |
| Concurrenta | 515 (70) |
| Priorb | 53 (7) |
| < 6 months of CYC | 29 (55) |
| ≥ 6 months of CYC | 20 (38) |
| Other immunosuppressant use - no. (%) | |
| Mycophenolic Acid | 59 (8) |
| Azathioprine | 119 (16) |
| Methotrexate | 33 (4) |
| Glucocorticoids | 698 (95) |
Except where indicated otherwise, values are the median (interquartile range). AAV = antineutrophil cytoplasmic autoantibody (ANCA) associated vasculitis; CYC = cyclophosphamide; LN = lupus nephritis; MN = membranous nephropathy; MCD/FSGS = minimal change disease / focal segmental glomerulosclerosis.
Concurrent use is defined as 8 weeks of daily oral cyclophosphamide beginning with the first dose of rituximab. Dosing was typically 2.5 mg/kg/day for the first week, and 1.5 mg/kg/day for 7 weeks, with adjustments made for renal function
Prior CYC is defined as a course of CYC administered prior to initiation of rituximab, as part of a separate induction of remission therapy. Missing data on 4 patients with unclear duration of CYC exposure.